< Zurück zu den aktuellen Neuigkeiten & Events

Knowledge Hub

EPO Enlarged Board of Appeal decision G4/19 – a European patent application can be refused by reason of the prohibition on double patenting

Juni 2021

The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’.  Such a refusal can be made even absent the European Patent Convention having an explicit double patenting provision.

The claiming of the same subject matter in two applications having the same filing or priority date to the same Applicant is referred to as double patenting.  The European Patent Convention does not contain an explicit prohibition against this practice. However, previous decisions against double patenting have relied upon a reference to general principles of patent law in EPC Contracting States embodied in Article 125 EPC.  For example, Section 18(5) of the UK Patents Act provides such an explicit double patenting provision.  It was argued that the double patenting provision embodied in Article 125 EPC only prevented double patenting in the case of applications filed on the same day or between a divisional application and its parent.

The Enlarged Board of Appeal confirmed that Article 125 EPC compelled the EPO to refuse applications for double patenting by taking into account national law of Contracting States.  Furthermore, the Enlarged Board found that double patenting is also prohibited in the case of internal priority i.e. where two applications benefit from the same priority and claim the same subject matter.

It is worth pointing out that the EPO only construes the probation on double patenting narrowly in order to prevent two patents claiming the same identical subject matter.  Therefore, where differences exist between the claims, the double patenting prohibition should not apply.

This article was prepared by HGF Partner Chris Benson. If you would like further advice on this or any other matter, please contact Chris. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Aktuelle Neuigkeiten

The Antibody Series #4 | pH‑Werte in Antikörperansprüchen – wenn „gleicher pH‑Wert“ zur unzulässigen Erweiterung wird

          Die Beschwerdekammern des EPA (BoA) sind die Berufungsinstanz, die Entscheidungen des EPA überprüft. In diesem Fall befassten sie sich mit einer Entscheidung zur Widerrufung eines …

Weiterlesen

The Antibody Series #3 | Codenamen von Antikörpern in Ansprüchen: Warum „ACZ885” nicht ausreicht, um den Antikörper zu definieren

          Die Beschwerdekammern des EPA (BoA) sind die Berufungsinstanz, die Entscheidungen des EPA überprüft. In diesem Fall prüften sie einen Anspruch, der einen Antikörper anhand eines …

Weiterlesen

Agritech Thymes: Unlocking the Soil Microbiome: Driving Agritech Innovation in the UK

The UK offers an ideal platform for harnessing the untapped potential of soil and plant microorganisms. Although much of my professional experience has focused on the human microbiome, I have …

Weiterlesen

The Antibody Series #2 | Definition anhand der Bindungsstärke in Antikörperansprüchen: Wenn „binds strongly … but only minimally …“ zu einer Falle mangelnder Klarheit wird.

            Die Definition eines Antikörpers anhand seiner Bindungsstärke ist in Patentansprüchen gängige Praxis, kann jedoch im Hinblick auf Artikel 84 EPÜ zur Klarheit schnell zu …

Weiterlesen

The Antibody Series #1 | Qualitätsmerkmale (CQAs) in Antikörperansprüchen: Wenn die Testmethode aus dem Anspruch herausgenommen werden kann

            Therapeutische Antikörper stehen im Mittelpunkt der Innovationen in der Biotechnologie und im Gesundheitswesen. Angesichts steigender regulatorischer Anforderungen und Qualitätserwartungen werden kritische Qualitätsmerkmale (CQAs) bei …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen